Diagnostic Value of Serum Cystatin C for Diabetic Nephropathy: a Meta-analysis

Overview

Journal BMC Endocr Disord

Publisher Biomed Central

Specialty Endocrinology

Date 2022 Jun 2

PMID 35655297

Authors

Xueling Liao

Yan Zhu

Chao Xue

Affiliations

Soon will be listed here.

Abstract

Background: Although dozens of studies have investigated the relationship between the content of serum cystatin C (Cys-C) and diabetic nephropathy (DN), the results are still controversial. Hence, This study aims to explore the accuracy of serum Cys-C for diagnosing DN by meta-analysis.

Methods: The studies about serum Cys-C diagnosing DN were searched from six online databases from inception to September 22, 2020. The data were processed by Stata 15.0 statistic software. The corresponding diagnostic effect sizes, such as sensitivity and specificity, were obtained. We drew a summary receiver operating characteristic (SROC) curve. We assess the risk of literature bias was following the QUADAS-2 guidelines.

Results: Twenty-six published studies were identified. The results showed a pooled sensitivity of 0.86 (95% confidence interval (CI): 0.82-0.90), specificity of 0.89 (95%CI: 0.85-0.92), positive likelihood ratio of 7.59 (95%CI: 5.66-10.19), negative likelihood ratio of 0.16 (95%CI: 0.12-0.21), and diagnostic odds ratio of 48.03 (95%CI: 30.64-75.29). The area under the SROC curve was given a value of 0.94 (95%CI: 0.91-0.96).

Conclusion: Serum cystatin C has an excellent diagnostic value with good sensitivity and specificity for diabetic nephropathy.

Citing Articles

[High serum cystatin C is an independent risk factor for poor renal prognosis in IgA nephropathy].

Tang T, Li L, Chen Y, Zhang L, Xu L, Li Z Nan Fang Yi Ke Da Xue Xue Bao. 2025; 45(2):379-386.

PMID: 40031982 PMC: 11875852. DOI: 10.12122/j.issn.1673-4254.2025.02.19.

Serum cystatin C, monocyte/high-density lipoprotein-C ratio, and uric acid for the diagnosis of coronary heart disease and heart failure.

Li M, Yuan D, Yang Z, Lu T, Zou X World J Clin Cases. 2024; 12(18):3461-3467.

PMID: 38983396 PMC: 11229902. DOI: 10.12998/wjcc.v12.i18.3461.

Metabolomics in diabetic nephropathy: Unveiling novel biomarkers for diagnosis (Review).

Luo Y, Zhang W, Qin G Mol Med Rep. 2024; 30(3).

PMID: 38963028 PMC: 11258608. DOI: 10.3892/mmr.2024.13280.

Dysregulation of miR-25-3p in Diabetic Nephropathy and Its Role in Inflammatory Response.

Chen H, Tian T, Wang D Biochem Genet. 2024; .

PMID: 38602597 DOI: 10.1007/s10528-024-10781-x.

Diagnostic challenges of diabetic kidney disease.

Vucic Lovrencic M, Bozicevic S, Smircic Duvnjak L Biochem Med (Zagreb). 2023; 33(3):030501.

PMID: 37545693 PMC: 10373061. DOI: 10.11613/BM.2023.030501.

References

. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis. 2012; 60(5):850-86. DOI: 10.1053/j.ajkd.2012.07.005. View

Sjostrom P, Tidman M, Jones I . Determination of the production rate and non-renal clearance of cystatin C and estimation of the glomerular filtration rate from the serum concentration of cystatin C in humans. Scand J Clin Lab Invest. 2005; 65(2):111-24. DOI: 10.1080/00365510510013523. View

Shlipak M, Mattes M, Peralta C . Update on cystatin C: incorporation into clinical practice. Am J Kidney Dis. 2013; 62(3):595-603. PMC: 3755100. DOI: 10.1053/j.ajkd.2013.03.027. View

Whiting P, Rutjes A, Westwood M, Mallett S, Deeks J, Reitsma J . QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155(8):529-36. DOI: 10.7326/0003-4819-155-8-201110180-00009. View

Olivarius N, Andreasen A, Keiding N, Mogensen C . Epidemiology of renal involvement in newly-diagnosed middle-aged and elderly diabetic patients. Cross-sectional data from the population-based study "Diabetes Care in General Practice", Denmark. Diabetologia. 1993; 36(10):1007-16. DOI: 10.1007/BF02374492. View

Salem N, El Helaly R, Ali I, Ebrahim H, Alayooti M, El Domiaty H . Urinary Cyclophilin A and serum Cystatin C as biomarkers for diabetic nephropathy in children with type 1 diabetes. Pediatr Diabetes. 2020; 21(5):846-855. DOI: 10.1111/pedi.13019. View

Christensson A, Grubb A, Nilsson J, Norrgren K, Sterner G, Sundkvist G . Serum cystatin C advantageous compared with serum creatinine in the detection of mild but not severe diabetic nephropathy. J Intern Med. 2004; 256(6):510-8. DOI: 10.1111/j.1365-2796.2004.01414.x. View

Iliadis F, Didangelos T, Ntemka A, Makedou A, Moralidis E, Gotzamani-Psarakou A . Glomerular filtration rate estimation in patients with type 2 diabetes: creatinine- or cystatin C-based equations?. Diabetologia. 2011; 54(12):2987-94. DOI: 10.1007/s00125-011-2307-1. View

. 5. Glycemic Targets. Diabetes Care. 2015; 39 Suppl 1:S39-46. DOI: 10.2337/dc16-S008. View

10.

Lee B, Ihm S, Choi M, Yoo H . The comparison of cystatin C and creatinine as an accurate serum marker in the prediction of type 2 diabetic nephropathy. Diabetes Res Clin Pract. 2007; 78(3):428-34. DOI: 10.1016/j.diabres.2007.06.015. View

11.

Beauvieux M, Le Moigne F, Lasseur C, Raffaitin C, Perlemoine C, Barthe N . New predictive equations improve monitoring of kidney function in patients with diabetes. Diabetes Care. 2007; 30(8):1988-94. DOI: 10.2337/dc06-2637. View

12.

Ascic-Buturovic B, Cavaljuga S . Cystatin C as a marker for detection of early renal failure in diabetes type 2 patients. Bosn J Basic Med Sci. 2005; 5(4):68-71. PMC: 7202172. DOI: 10.17305/bjbms.2005.3237. View

13.

Chappell F, Raab G, Wardlaw J . When are summary ROC curves appropriate for diagnostic meta-analyses?. Stat Med. 2009; 28(21):2653-68. DOI: 10.1002/sim.3631. View

14.

Kimura T, Ikeda H, Fujikawa J, Nomura K, Aoyama T, Wada Y . Usefulness of serum cystatin C in Japanese patients with type 2 diabetes mellitus and nephropathy. Diabetes Res Clin Pract. 2009; 83(2):e58-61. DOI: 10.1016/j.diabres.2008.11.032. View

15.

Pucci L, Triscornia S, Lucchesi D, Fotino C, Pellegrini G, Pardini E . Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. Clin Chem. 2007; 53(3):480-8. DOI: 10.1373/clinchem.2006.076042. View

16.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

17.

Rigalleau V, Beauvieux M, Le Moigne F, Lasseur C, Chauveau P, Raffaitin C . Cystatin C improves the diagnosis and stratification of chronic kidney disease, and the estimation of glomerular filtration rate in diabetes. Diabetes Metab. 2008; 34(5):482-9. DOI: 10.1016/j.diabet.2008.03.004. View

18.

Jeon Y, Kim M, Huh J, Mok J, Song S, Kim S . Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes. J Korean Med Sci. 2011; 26(2):258-63. PMC: 3031011. DOI: 10.3346/jkms.2011.26.2.258. View

19.

Yan S, Liu J, Tian H, Li C, Li J, Shao Y . Clinical and pathological analysis of renal damage in elderly patients with type 2 diabetes mellitus. Clin Exp Med. 2015; 16(3):437-42. DOI: 10.1007/s10238-015-0362-5. View

20.

Srivastava A, Adams-Huet B, Vega G, Toto R . Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy. J Investig Med. 2016; 64(6):1102-8. PMC: 4975815. DOI: 10.1136/jim-2016-000102. View